Basilea Pharmaceutica AG (BSLN.SW)
CHF 42.1
(2.93%)
CHF 42.1
(2.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 130.84 Million CHF | 8.17% |
| 2022 | 120.96 Million CHF | -2.49% |
| 2021 | 124.05 Million CHF | 19.77% |
| 2020 | 103.57 Million CHF | -10.33% |
| 2019 | 115.51 Million CHF | 1479.34% |
| 2018 | 7.31 Million CHF | -80.47% |
| 2017 | 37.44 Million CHF | 207.2% |
| 2016 | 12.18 Million CHF | 268.11% |
| 2015 | -7.25 Million CHF | 38.96% |
| 2014 | -11.87 Million CHF | 4.2% |
| 2013 | -12.39 Million CHF | -122.99% |
| 2012 | 53.93 Million CHF | -15.44% |
| 2011 | 63.78 Million CHF | -44.8% |
| 2010 | 115.55 Million CHF | 358.58% |
| 2009 | 25.19 Million CHF | 115.46% |
| 2008 | 11.69 Million CHF | 48.07% |
| 2007 | 7.89 Million CHF | 9.95% |
| 2006 | 7.18 Million CHF | -76.44% |
| 2005 | 30.49 Million CHF | 10536.38% |
| 2004 | 286.7 Thousand CHF | -24.4% |
| 2003 | 379.22 Thousand CHF | 85.58% |
| 2002 | 204.34 Thousand CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 24.57 Million CHF | 0.0% |
| 2023 Q4 | 55.93 Million CHF | 0.0% |
| 2023 Q2 | 74.9 Million CHF | 0.0% |
| 2023 FY | 130.84 Million CHF | 8.17% |
| 2022 Q4 | 79.43 Million CHF | 0.0% |
| 2022 Q2 | 43.72 Million CHF | 0.0% |
| 2022 FY | 120.96 Million CHF | -2.49% |
| 2021 Q2 | 40.67 Million CHF | 0.0% |
| 2021 Q4 | 83.37 Million CHF | 0.0% |
| 2021 FY | 124.05 Million CHF | 19.77% |
| 2020 Q2 | 56.24 Million CHF | 0.0% |
| 2020 FY | 103.57 Million CHF | -10.33% |
| 2020 Q4 | 47.33 Million CHF | 0.0% |
| 2019 Q4 | 61.69 Million CHF | 0.0% |
| 2019 Q2 | 53.81 Million CHF | 0.0% |
| 2019 FY | 115.51 Million CHF | 1479.34% |
| 2018 FY | 7.31 Million CHF | -80.47% |
| 2018 Q2 | -4.43 Million CHF | 0.0% |
| 2018 Q4 | 11.74 Million CHF | 0.0% |
| 2017 Q2 | 15.44 Million CHF | 0.0% |
| 2017 Q4 | 21.99 Million CHF | 0.0% |
| 2017 FY | 37.44 Million CHF | 207.2% |
| 2016 Q2 | 1.97 Million CHF | 0.0% |
| 2016 FY | 12.18 Million CHF | 268.11% |
| 2016 Q4 | 10.21 Million CHF | 0.0% |
| 2015 Q2 | -6.39 Million CHF | 0.0% |
| 2015 Q4 | -856 Thousand CHF | 0.0% |
| 2015 FY | -7.25 Million CHF | 38.96% |
| 2014 Q4 | -4.64 Million CHF | 0.0% |
| 2014 FY | -11.87 Million CHF | 4.2% |
| 2014 Q2 | -7.23 Million CHF | 0.0% |
| 2013 Q4 | -6.16 Million CHF | 0.0% |
| 2013 Q2 | -6.23 Million CHF | 0.0% |
| 2013 FY | -12.39 Million CHF | -122.99% |
| 2012 Q2 | 13.48 Million CHF | 0.0% |
| 2012 Q1 | 13.48 Million CHF | -0.0% |
| 2012 Q4 | 10.34 Million CHF | -23.29% |
| 2012 FY | 53.93 Million CHF | -15.44% |
| 2012 Q3 | 13.48 Million CHF | -0.0% |
| 2011 FY | 63.78 Million CHF | -44.8% |
| 2011 Q3 | 15.94 Million CHF | -0.0% |
| 2011 Q4 | 13.48 Million CHF | -15.44% |
| 2011 Q2 | 15.94 Million CHF | 0.0% |
| 2011 Q1 | 15.94 Million CHF | -0.0% |
| 2010 Q4 | 15.94 Million CHF | -44.8% |
| 2010 FY | 115.55 Million CHF | 358.58% |
| 2010 Q2 | 28.88 Million CHF | 0.0% |
| 2010 Q1 | 28.88 Million CHF | 0.0% |
| 2010 Q3 | 28.88 Million CHF | 0.0% |
| 2009 FY | 25.19 Million CHF | 115.46% |
| 2009 Q1 | 6.29 Million CHF | -0.0% |
| 2009 Q2 | 6.29 Million CHF | 0.0% |
| 2009 Q3 | 6.29 Million CHF | -0.0% |
| 2009 Q4 | 28.88 Million CHF | 358.58% |
| 2008 FY | 11.69 Million CHF | 48.07% |
| 2008 Q4 | 6.29 Million CHF | 115.46% |
| 2008 Q1 | 2.92 Million CHF | 0.0% |
| 2008 Q2 | 2.92 Million CHF | 0.0% |
| 2008 Q3 | 2.92 Million CHF | 0.0% |
| 2007 Q2 | 1.97 Million CHF | 0.0% |
| 2007 Q4 | 2.92 Million CHF | 48.07% |
| 2007 Q3 | 1.97 Million CHF | 0.0% |
| 2007 Q1 | 1.97 Million CHF | 0.0% |
| 2007 FY | 7.89 Million CHF | 9.95% |
| 2006 Q2 | 1.79 Million CHF | 0.0% |
| 2006 Q3 | 1.79 Million CHF | 0.0% |
| 2006 Q4 | 1.97 Million CHF | 9.95% |
| 2006 FY | 7.18 Million CHF | -76.44% |
| 2006 Q1 | 1.79 Million CHF | 0.0% |
| 2005 Q4 | 1.79 Million CHF | -76.44% |
| 2005 Q3 | 7.62 Million CHF | 0.0% |
| 2005 Q1 | 7.62 Million CHF | 0.0% |
| 2005 Q2 | 7.62 Million CHF | 0.0% |
| 2005 FY | 30.49 Million CHF | 10536.38% |
| 2004 FY | 286.7 Thousand CHF | -24.4% |
| 2004 Q1 | 71.67 Thousand CHF | 0.0% |
| 2004 Q2 | 71.67 Thousand CHF | 0.0% |
| 2004 Q3 | 71.67 Thousand CHF | 0.0% |
| 2004 Q4 | 7.62 Million CHF | 10536.38% |
| 2003 Q1 | 94.8 Thousand CHF | 0.0% |
| 2003 Q3 | 94.8 Thousand CHF | 0.0% |
| 2003 Q4 | 71.67 Thousand CHF | -24.4% |
| 2003 Q2 | 94.8 Thousand CHF | 0.0% |
| 2003 FY | 379.22 Thousand CHF | 85.58% |
| 2002 Q3 | 51.08 Thousand CHF | 0.0% |
| 2002 FY | 204.34 Thousand CHF | 0.0% |
| 2002 Q2 | 51.08 Thousand CHF | 0.0% |
| 2002 Q1 | 51.08 Thousand CHF | 0.0% |
| 2002 Q4 | 94.8 Thousand CHF | 85.58% |
| 2001 Q4 | 51.08 Thousand CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Addex Therapeutics Ltd | -5.31 Million CHF | 2560.186% |
| BB Biotech AG | -199.56 Million CHF | 165.562% |
| Evolva Holding SA | -2.58 Million CHF | 5166.212% |
| Idorsia Ltd | 145.23 Million CHF | 9.912% |
| Kuros Biosciences AG | 22.87 Million CHF | -472.053% |
| Molecular Partners AG | -40.8 Million CHF | 420.639% |
| Relief Therapeutics Holding AG | -10.85 Million CHF | 1304.899% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | -31.439% |